Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers - Wikidata - wikimedia - TriplyDB

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

http://www.wikidata.org/entity/Q24611483

about

Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants The impact of the myeloid response to radiation therapy Design and development of a robotized system coupled to µCT imaging for intratumoral drug evaluation in a HCC mouse model Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium.Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.Naturally occurring reoviruses for human cancer therapy.Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors.Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.Reovirus in cancer therapy: an evidence-based review New paradigms and future challenges in radiation oncology: an update of biological targets and technology.Reovirus: a targeted therapeutic--progress and potential.Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling.Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions.Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.Current status of gene therapy for breast cancer: progress and challenges.Asynchronous leptomeningeal carcinomatosis from pancreatic cancer: a case report and review of the literature.Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.African Swine Fever Virus NP868R Capping Enzyme Promotes Reovirus Rescue during Reverse Genetics by Promoting Reovirus Protein Expression, Virion Assembly, and RNA Incorporation into Infectious Virions.Investigational drugs for head and neck cancer.Oncolytic virotherapy for multiple myeloma: past, present, and future.Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.Reduction of virion-associated σ1 fibers on oncolytic reovirus variants promotes adaptation toward tumorigenic cells.Oncolytic virotherapy for head and neck cancer: current research and future developments.Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.

P2860

Q26750568-7C36CAF9-0F8A-4A07-837E-660F9C4C5023 Q26752807-F66D629C-6B1E-4A60-85C3-929C6A3DE887 Q26775030-76A59070-468A-44EF-BB60-67BE65859651 Q26775033-8FF8598F-7629-4BAA-869B-CCA730C388ED Q26851643-4B765BED-E79A-4047-93C3-CC5A34D4BE51 Q27312299-458BAFF6-E5B2-4FD9-BA04-6CFA10BBED69 Q28485141-10273B7D-B376-413B-A8EA-8A2A8EE136A7 Q33418048-5FDF4929-79AB-449E-A4E7-70882C5E8459 Q34348199-7A0E97CE-4125-435E-B992-8AC9CB63A50C Q34393001-E3E816D8-1AB6-41AB-AD43-98253D46F11F Q34763999-47565B58-0BAA-47D3-A4E8-2FDCE640D746 Q35061974-7429D62B-2EDA-43CE-A091-9DE5C8061DB9 Q35224368-77854E8A-20A9-4715-A998-00E593F6E2D1 Q35262964-EFEDFEFD-012F-49E5-B09E-E00439977EEF Q35596563-31B428DD-DFE3-415E-B2E4-ED13D81AEF10 Q35812675-A0836A8B-5D86-466D-9103-3F39EF9E51AC Q36078485-0091F7DA-A151-4526-B0AD-3B3F3037C44A Q36436992-E2B1919F-FD9A-4233-8DF3-C214D5861D8B Q36574519-E92BF9D8-F0A0-40F3-818C-BCC1984BC4B1 Q36582819-786EC754-3A5A-4B5A-8ED5-0C22BD2A43B1 Q36673729-C96DF55B-5B13-458D-AA5C-9D5DD340065F Q36766032-2793AE38-2657-4B7F-86B4-82DEA78D4747 Q36766052-1007F0C4-4F77-4420-AD26-46C6B8BD1E8C Q37031909-7B387A2C-3DFA-4923-9912-BBB87AF80327 Q37160539-6CC9A8A4-6D48-43A0-BF84-8950ABC06FC6 Q37360608-972CEED1-E18B-4E68-B05C-14D559791248 Q37565521-5C507759-9326-4593-A576-F844204A8F06 Q37977063-3C8FE9B1-7B41-4791-A257-6689CFA281FB Q38058884-E3569D6B-D48F-4F9D-B4F3-ED7ECEA623F5 Q38221692-76AD3CC3-19E9-44BC-99DD-E38C75F08D9A Q38270806-44A5CEF0-7061-42A1-A361-13A19D49A7D5 Q38548938-E35CDF3B-BCC6-4F14-BA0A-8DD097D6B9CD Q38647883-C2426BC3-8891-4ADF-806E-B12F21675AF6 Q38712130-17D4D5BB-69CF-4006-AD1B-3AD5A02E05FD Q38800788-E067C892-504A-43D6-AB84-940C448FDCEC Q38803056-9840DFFA-86A2-47D3-8C4F-676AE44A1794 Q38912287-F7B0FB95-3B9C-4B83-A693-6B54A4721CFB Q38912745-A786198A-A474-470D-B15B-16DBAB25867B Q38924562-A1251DF9-2E5F-428C-B43E-F5E12AA4236E Q39159172-72C070E6-6AE6-4045-9539-25FEECBCD3C4

P2860

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

http://www.wikidata.org/entity/Q24611483

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Two-stage phase I dose-escalat ...... patients with advanced cancers

@ast

Two-stage phase I dose-escalat ...... patients with advanced cancers

@en

Two-stage phase I dose-escalat ...... patients with advanced cancers

@nl

type

label

Two-stage phase I dose-escalat ...... patients with advanced cancers

@ast

Two-stage phase I dose-escalat ...... patients with advanced cancers

@en

Two-stage phase I dose-escalat ...... patients with advanced cancers

@nl

prefLabel

Two-stage phase I dose-escalat ...... patients with advanced cancers

@ast

Two-stage phase I dose-escalat ...... patients with advanced cancers

@en

Two-stage phase I dose-escalat ...... patients with advanced cancers

@nl

P1433

Q24611483-D4878457-1D6E-4778-ADF1-F5C3CBA33ABA

P1476

Q24611483-D632C2B4-DFDD-4020-A8D9-9BB2156E2193

P2093

Q24611483-0E3BED98-8A15-45D4-8839-18EB4AC4313C

Q24611483-263D0023-1597-4164-B448-E5043EEC8B5E

Q24611483-2E5CBD88-9932-4D5D-B4B1-48183472CBDC

Q24611483-3479A2FA-6185-45D4-BA11-E67EEEFC796C

Q24611483-42367C82-61E8-40F7-8D8D-22EB1FC20039

Q24611483-59B2E2C8-17D6-4B6F-9C33-859E700BD7A6

Q24611483-623DBA02-95C2-4546-8D33-7B8ED6CC8C51

Q24611483-6265AF2F-7D6F-4AAF-AF94-0DEBFAA12E7D

Q24611483-6929476B-895F-4A23-94FC-38D0189C0268

Q24611483-6BE2B5A7-662E-4652-973C-25D95503962D

P2860

Q24611483-09843C41-E8E3-4007-A91F-849B25031B19

Q24611483-12036B40-ADAD-4D15-8D55-34A528BFD4C4

Q24611483-12870385-7841-46FF-AE49-6AADA4989EE2

Q24611483-2E92D056-1CE8-4A25-8A26-2FA58FBACA2A

Q24611483-3A5550A5-7A74-4B02-B1AF-788ACA1EEF16

Q24611483-40FE6CE5-E5A7-4AC8-B91B-DDC0245EDCFE

Q24611483-4B34E286-0DAA-4598-8417-A3475BF8594E

Q24611483-4BC0810B-A144-46E3-97AE-A26E2C6EB2F4

Q24611483-5B8909AB-F1D4-4711-BCE3-08847FF328C7

Q24611483-6522526E-8DA1-4B45-9701-FC84BE7EA652

P304

Q24611483-BCA07D49-3349-4F61-95A6-CC2037382130

P31

Q24611483-A14AB8BA-EE8F-425C-B19D-F7D284859951

P3181

Q24611483-5397B186-5416-4658-B7D6-F7FE18F33048

P356

Q24611483-B0126CB6-EC10-4BCF-A9ED-7096567729C5

P407

Q24611483-F80F7FC0-0960-45BE-8978-5ECE34064833

P433

Q24611483-5A09E5B6-BAD0-4434-B626-1E406C5E1644

P478

Q24611483-DD892999-4ECA-4A47-A2F4-936F701E5881

P577

Q24611483-CC923AFE-ACBF-4166-986D-872979F0C81E

P698

Q24611483-DAAB630B-C762-4C64-8A4E-BC9C36BB5A81

P921

Q24611483-51095BCE-FC28-4A22-AB66-626B35462656

Q24611483-A4E9A39D-A456-46F7-9DA4-6690139CF312

Q24611483-F34D2EB2-4D21-4331-A604-619808C1E052

P932

Q24611483-0DC2838A-6468-43D4-B984-DF8E6A798B5D

P3181

P356

1078-0432.CCR-10-0054

P1433

Clinical Cancer Research

P1476

Two-stage phase I dose-escalat ...... patients with advanced cancers

@en

P2093

Alan A Melcher

http://www.w3.org/2001/XMLSchema#string

Christine L White

http://www.w3.org/2001/XMLSchema#string

Christopher M Nutting

http://www.w3.org/2001/XMLSchema#string

Dean Harris

http://www.w3.org/2001/XMLSchema#string

Debbie Beirne

http://www.w3.org/2001/XMLSchema#string

Eleni M Karapanagiotou

http://www.w3.org/2001/XMLSchema#string

Hardev S Pandha

http://www.w3.org/2001/XMLSchema#string

Johann S Debono

http://www.w3.org/2001/XMLSchema#string

Kate Newbold

http://www.w3.org/2001/XMLSchema#string

Katie R Twigger

http://www.w3.org/2001/XMLSchema#string

P2860

Interactions between ionizing radiation and drugs in head and neck cancer: how can we maximize the therapeutic index?

Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy.

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.

The RAS signal transduction pathway and its role in radiation sensitivity.

Oncolytic viral therapies - the clinical experience.

Combining radiation and cancer gene therapy: a potential marriage of physical and biological targeting?

Exploiting synergies between radiation and oncolytic viruses.

Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.

Novel targeted radiosensitisers in cancer treatment.

Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.

P304

3067-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2449341

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-10-0054

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20484020

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

3907942

http://www.w3.org/2001/XMLSchema#string